The Effect of Canakinumab on Clinical Outcomes in Patients With COVID-19: A Meta-Analysis

    March 2022 in “ Journal of Infection ”
    Guangyu Ao, Yushu Wang, Toni Li, Carolyn Tran, Qing Yang
    TLDR Canakinumab's effect on COVID-19 outcomes is unclear.
    This meta-analysis, which included 6 studies with 1,121 adult COVID-19 patients, found that canakinumab treatment was associated with a lower risk of mortality and reduced acute inflammation, as shown by decreased serum CRP levels. Canakinumab, targeting IL-1β, potentially mitigated cytokine storms linked to severe COVID-19 outcomes. Despite the small sample size, the study suggested canakinumab could be a beneficial anti-inflammatory treatment for COVID-19, though further research was needed to confirm these findings.
    Discuss this study in the Community →